Novel Treatment for Breast Cancer: Truncated Galectin-3
乳腺癌的新疗法:截短的半乳糖凝集素 3
基本信息
- 批准号:6489447
- 负责人:
- 金额:$ 25.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-07-10 至 2003-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
Despite the available treatments breast cancer ranks second as the cause of
death from cancer in women primarily due to metastases of the primary tumor to
other sites in the body. We will extend our preliminary study of the
anticancer activity of recombinant human galectin-3 N-terminally truncated by
collagenase in an orthotopic mouse model of metastatic breast cancer.
We postulate that galectin-3 truncated by collagenase blocks the binding sites
for galectin-3 and prevent its cell crosslinking and other activities. We
will determine the in vivo efficacy of an analogous galectin-3 variant (delta
107) produced in E. coli and compare it with that of galectin-3 truncated
enzymatically. We will perform a dose-response analysis to firmly establish
the activity of the delta 107 variant, and address the optimal dose. We will
also test the anticancer activity of a slightly longer mutant of galectin-3.
A series of cell-based assays would be used to compare the in vitro activities
of the galectin-3 variants with intact galectin-3. Further development of
truncated galectin-3 as a clinical candidate for breast cancer would be the
focus of the Phase II research.
PROPOSED COMMERCIAL APPLICATION:
An estimated 40,800 Americans are expected to die of breast cancer this year. A
therapy that primarily acts to reduce metastasis could be effective in treating breast
cancer, especially early stage cancer. If galectin-3 has a reduced incidence of side
effects this would increase its attractiveness. The commercial potential of breast
cancer therapeutics is large.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Constance M John其他文献
SPINAL EXPRESSION OF NEUROTROPHIN-3 PREVENTS MUSCULAR CHANGES OF THE URINARY BLADDER AFTER SPINAL CORD CONTUSION IN RATS
- DOI:
10.1016/s0022-5347(08)61027-7 - 发表时间:
2008-04-01 - 期刊:
- 影响因子:
- 作者:
Thomas M Fandel;Linda J Noble-Haeusslein;Alpa A Mahuvakar;Constance M John;Tom F Lue;Emil A Tanagho - 通讯作者:
Emil A Tanagho
Constance M John的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Constance M John', 18)}}的其他基金
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction
半乳糖凝集素3抑制治疗心肌梗死后重构
- 批准号:
9202835 - 财政年份:2016
- 资助金额:
$ 25.55万 - 项目类别:
Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction
半乳糖凝集素3抑制治疗心肌梗死后重构
- 批准号:
9453176 - 财政年份:2016
- 资助金额:
$ 25.55万 - 项目类别:
Protein inhibitor of galectin-3 to limit fibrosis after myocardial infarction
Galectin-3 蛋白抑制剂可限制心肌梗死后纤维化
- 批准号:
8597803 - 财政年份:2013
- 资助金额:
$ 25.55万 - 项目类别:
Model of the Human Testis for Reproductive Toxicology
用于生殖毒理学的人类睾丸模型
- 批准号:
8201518 - 财政年份:2011
- 资助金额:
$ 25.55万 - 项目类别:
Human Sertoli Cell Model for Study of Male Reproductive Function and Toxicity
用于研究男性生殖功能和毒性的人类支持细胞模型
- 批准号:
7327186 - 财政年份:2007
- 资助金额:
$ 25.55万 - 项目类别:
Novel biomarkers for neuronal damage in multiple sclerosis
多发性硬化症神经元损伤的新型生物标志物
- 批准号:
7053269 - 财政年份:2006
- 资助金额:
$ 25.55万 - 项目类别:
Novel Treatment for Breast Cancer: Truncated Galectin-3
乳腺癌的新疗法:截短的半乳糖凝集素 3
- 批准号:
6401370 - 财政年份:2001
- 资助金额:
$ 25.55万 - 项目类别:
PLACENTAL CELLS FOR PROTECTION OF IMPLANTED B ISLETS
用于保护植入 B 胰岛的胎盘细胞
- 批准号:
6352407 - 财政年份:2000
- 资助金额:
$ 25.55万 - 项目类别:
相似海外基金
Pathology of Breast Neoplasms determined by MRS
MRS 测定乳腺肿瘤的病理学
- 批准号:
nhmrc : 950215 - 财政年份:1995
- 资助金额:
$ 25.55万 - 项目类别:
NHMRC Project Grants